OBIO vs. CBLL, BVS, AVNS, IRMD, BFLY, SIBN, KIDS, TMCI, SMLR, and NNOX
Should you be buying Orchestra BioMed stock or one of its competitors? The main competitors of Orchestra BioMed include CeriBell (CBLL), Bioventus (BVS), Avanos Medical (AVNS), Iradimed (IRMD), Butterfly Network (BFLY), SI-BONE (SIBN), OrthoPediatrics (KIDS), Treace Medical Concepts (TMCI), Semler Scientific (SMLR), and Nano-X Imaging (NNOX). These companies are all part of the "medical equipment" industry.
Orchestra BioMed vs.
CeriBell (NASDAQ:CBLL) and Orchestra BioMed (NASDAQ:OBIO) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, community ranking, media sentiment, risk, profitability, analyst recommendations and dividends.
CeriBell presently has a consensus target price of $32.60, indicating a potential upside of 54.94%. Orchestra BioMed has a consensus target price of $16.25, indicating a potential upside of 207.77%. Given Orchestra BioMed's higher possible upside, analysts clearly believe Orchestra BioMed is more favorable than CeriBell.
CeriBell has a net margin of 0.00% compared to Orchestra BioMed's net margin of -2,179.33%. CeriBell's return on equity of 0.00% beat Orchestra BioMed's return on equity.
Orchestra BioMed received 4 more outperform votes than CeriBell when rated by MarketBeat users.
53.6% of Orchestra BioMed shares are held by institutional investors. 6.7% of Orchestra BioMed shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
In the previous week, CeriBell had 1 more articles in the media than Orchestra BioMed. MarketBeat recorded 1 mentions for CeriBell and 0 mentions for Orchestra BioMed. CeriBell's average media sentiment score of 0.12 beat Orchestra BioMed's score of 0.00 indicating that CeriBell is being referred to more favorably in the media.
CeriBell has higher revenue and earnings than Orchestra BioMed.
Summary
CeriBell beats Orchestra BioMed on 7 of the 12 factors compared between the two stocks.
Get Orchestra BioMed News Delivered to You Automatically
Sign up to receive the latest news and ratings for OBIO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Orchestra BioMed Competitors List
Related Companies and Tools
This page (NASDAQ:OBIO) was last updated on 1/20/2025 by MarketBeat.com Staff
